<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02577055</url>
  </required_header>
  <id_info>
    <org_study_id>P140311</org_study_id>
    <nct_id>NCT02577055</nct_id>
  </id_info>
  <brief_title>Fertility After Myomectomy Versus Uterine Artery Embolization for Symptomatic Uterine Fibroids</brief_title>
  <acronym>Lune2</acronym>
  <official_title>Fertility After Myomectomy Versus Uterine Artery Embolization for Symptomatic Uterine Fibroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of this study:&#xD;
&#xD;
      To establish the superiority of myomectomy versus Uterine Artery Embolization, in women with&#xD;
      multiple symptomatic fibroids and no other infertility factor, seeking to conceive.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      The use of uterine artery embolization (UAE) to treat symptomatic fibroids in women seeking&#xD;
      future fertility remains a matter of debate, because of possible adverse effects on ovarian&#xD;
      reserve and embryo implantation. In women with associated infertility factors, not eligible&#xD;
      for myomectomy, poor fertility was obtained after UAE. On the other hand, fertility of women&#xD;
      eligible for surgical myomectomy, deciding to have a UAE, compares favourably with the&#xD;
      fertility obtained after myomectomy.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Eligible women will be explored to pull out any other infertility factors such as:&#xD;
&#xD;
        -  tubal factors (no hydrosalpinx at MRI, tubal permeability assessed by&#xD;
           hysterosalpingography and/or negative serology of for Chlamydia)&#xD;
&#xD;
        -  Endometriosis (clinical history and examination, MRI)&#xD;
&#xD;
        -  Ovarian factors (normal AMH dosage, and Antral follicular count)&#xD;
&#xD;
        -  Male factors (normal spermogram of the Partner if possible)&#xD;
&#xD;
      Women will be treated with fertility sparing ultra selective uterine artery embolization, or&#xD;
      surgical removal of multiple myomas.&#xD;
&#xD;
      A six months convalescence/cicatrisation period will be respected, then women will be allowed&#xD;
      to intend to conceive.&#xD;
&#xD;
      Several elements will be prospectively followed:&#xD;
&#xD;
        -  Spontaneous pregnancy from 6 months to 18 months after treatment&#xD;
&#xD;
        -  Pregnancy outcomes&#xD;
&#xD;
        -  Symptoms and quality of live with UFS-QoL and WHQ questionnaires, at 3, 6, 12 and 18&#xD;
           months after treatment&#xD;
&#xD;
        -  Uterine size with MRI, before and 3 months after treatment.&#xD;
&#xD;
        -  Aspect of the uterine cavity with hysteroscopy before and 3 months after treatment.&#xD;
&#xD;
        -  Ovarian reserve with AMH dosage, and Antral follicular count before and 3 months after&#xD;
           treatment.&#xD;
&#xD;
        -  Volume and molecular pattern of the endometrium at the implantation window before and 3&#xD;
           months after treatment (optional).&#xD;
&#xD;
        -  Treatment's adverse effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Actual">October 16, 2019</completion_date>
  <primary_completion_date type="Actual">October 16, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of live birth in a year of fertility attempt</measure>
    <time_frame>18 months</time_frame>
    <description>Women will be allowed to attempt fertility 6 months after treatment. Effective fertility attempts will be prospectively followed. Final fertility will be assessed one year later.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of adverse effects on fertility (ovarian reserve markers)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of adverse effects on fertility (state of the uterine cavity)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of adverse effects on fertility (state of the endometrium</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of symptoms related to fibroids With UFS-QoL questionnaires</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of symptoms related to fibroids With UFS-QoL questionnaires</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of symptoms related to fibroids With UFS-QoL questionnaires</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of symptoms related to fibroids With UFS-QoL questionnaires</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life With QSF questionnaires, a French version of the WHQ questionnaire</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life With QSF questionnaires, a French version of the WHQ questionnaire</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life With QSF questionnaires, a French version of the WHQ questionnaire</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life With QSF questionnaires, a French version of the WHQ questionnaire</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse effects during pregnancy : Rate of Miscarriage</measure>
    <time_frame>Until 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse effects during pregnancy : extra-uterine pregnancy</measure>
    <time_frame>until 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse effects during pregnancy : small for gestational age</measure>
    <time_frame>Until 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse effects during pregnancy : foetal death</measure>
    <time_frame>Until 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse effects during pregnancy : uterine rupture</measure>
    <time_frame>Until 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse effects during pregnancy : abnormal placental position and implantation</measure>
    <time_frame>Until 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse effects during pregnancy : preterm delivery</measure>
    <time_frame>Until 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse effects during pregnancy : delivery hemorrhagy</measure>
    <time_frame>Until 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of adverse effects in the newborn</measure>
    <time_frame>At day 3 of life</time_frame>
    <description>Rate of small for gestational age, delivery presentation, health of newborn children (Apgar score, cord pH, admission in the neonatology service)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Leiomyoma</condition>
  <arm_group>
    <arm_group_label>myomectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will be treated with surgical removal of all fibroids, either by laparoscopic or abdominal route</description>
  </arm_group>
  <arm_group>
    <arm_group_label>embolisation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women will be treated with fertility sparing uterine arteries embolization (i..e. with ultra thin catheter, and particles' diameter &gt; 500µm)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>myomectomy</intervention_name>
    <description>Surgical ablation of all fibroids</description>
    <arm_group_label>myomectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>embolisation</intervention_name>
    <description>Embolisation of the peri-myoma vascular network, with non-resorbable particles of &gt;500 µm diameter, using an ultra thin catheter introduced through the vascular network up to the uterine arteries under radioscopic control.</description>
    <arm_group_label>embolisation</arm_group_label>
    <other_name>Fertility sparing ultra selective uterine artery embolization</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women aged ≥ 18 and ≤ 43 years old&#xD;
&#xD;
          -  At least one interstitial fibroid more than 3 cm on MRIat MRI)&#xD;
&#xD;
          -  with symptoms: genital bleeding, chronic pelvic pain or heaviness, anemia, or&#xD;
             infertility &gt; 1 year.&#xD;
&#xD;
          -  With immediate desire to conceive&#xD;
&#xD;
          -  without assisted reproductive indication: no tubal infertility, menstrual&#xD;
             irregularities, hydrosalpinx, endometriosis, adenomyosis, or male infertility.&#xD;
&#xD;
          -  Patient with health insurance, who can read and understand French and who has given&#xD;
             written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ongoing regnancy&#xD;
&#xD;
          -  Emergency Situation&#xD;
&#xD;
          -  Contraindication to surgery or uterine embolization: allergy to contrast medium ,&#xD;
             renal failure, immunodeficiency, contraindication to anesthesia, subserosal or&#xD;
             submucosal pedunculated fibroids, fibroids with largest diameter inside of the uterine&#xD;
             cavity&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>43 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine Torre, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculté de médecine de Montpellier-Nîmes, Université de Montpellier 1, France.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arnaud Fauconnier, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>UFR des sciences de la santé Simone Veil, Université de Versailles Saint Quentin en Yvelines, France.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Département de Médecine de la Reproduction, Centre Hospitalier Régionnal Universitaire de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Gupta JK, Sinha A, Lumsden MA, Hickey M. Uterine artery embolization for symptomatic uterine fibroids. Cochrane Database Syst Rev. 2012 May 16;(5):CD005073. doi: 10.1002/14651858.CD005073.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;(12):CD005073.</citation>
    <PMID>22592701</PMID>
  </reference>
  <reference>
    <citation>Torre A, Paillusson B, Fain V, Labauge P, Pelage JP, Fauconnier A. Uterine artery embolization for severe symptomatic fibroids: effects on fertility and symptoms. Hum Reprod. 2014 Mar;29(3):490-501. doi: 10.1093/humrep/det459. Epub 2014 Jan 15.</citation>
    <PMID>24430777</PMID>
  </reference>
  <reference>
    <citation>Mara M, Maskova J, Fucikova Z, Kuzel D, Belsan T, Sosna O. Midterm clinical and first reproductive results of a randomized controlled trial comparing uterine fibroid embolization and myomectomy. Cardiovasc Intervent Radiol. 2008 Jan-Feb;31(1):73-85. Epub 2007 Oct 18.</citation>
    <PMID>17943348</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 20, 2015</study_first_submitted>
  <study_first_submitted_qc>October 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2015</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leiomyoma</keyword>
  <keyword>Uterine Artery Embolization</keyword>
  <keyword>Surgery</keyword>
  <keyword>childbearing age</keyword>
  <keyword>Fertility</keyword>
  <keyword>Noninferiority trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

